Recent News for PMN - ProMIS Neurosciences Inc.

Date	Title
Jul 30	ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
Jul 26	ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
Jul 26	ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
May 15	ProMIS Neurosciences GAAP EPS of -$0.19
May 14	ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights